alexa Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.
Immunology

Immunology

Rheumatology: Current Research

Author(s): Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP,

Abstract Share this page

Abstract OBJECTIVE: To identify baseline characteristics of patients with scleroderma-related interstitial lung disease (SSc-ILD) that could serve as predictors of the most favorable response to 12-month treatment with oral cyclophosphamide (CYC). METHODS: Regression analyses were retrospectively applied to the Scleroderma Lung Study data in order to identify baseline characteristics that correlated with the absolute change in forced vital capacity (FVC) (\% predicted values) and the placebo-adjusted change in \% predicted FVC over time (the CYC treatment effect). RESULTS: Completion of the CYC arm of the Scleroderma Lung Study was associated with a placebo-adjusted improvement in the \% predicted FVC of 2.11\% at 12 months, which increased to 4.16\% when patients were followed up for another 6 months (P=0.014). Multivariate regression analyses identified the maximal severity of reticular infiltrates (assessed as maximum fibrosis scores) on high-resolution computed tomography (HRCT) at baseline, the modified Rodnan skin thickness score (MRSS) at baseline, and the Mahler baseline dyspnea index as independent correlates of treatment response. When patients were stratified on the basis of whether 50\% or more of any lung zone was involved by reticular infiltrates on HRCT and/or whether patients exhibited an MRSS of at least 23, a subgroup of patients emerged in whom there was an average CYC treatment effect of 9.81\% at 18 months (P<0.001). Conversely, there was no treatment effect (a -0.58\% difference) in patients with less severe HRCT findings and a lower MRSS at baseline. CONCLUSION: A retrospective analysis of the Scleroderma Lung Study data identified the severity of reticular infiltrates on baseline HRCT and the baseline MRSS as patient features that might be predictive of responsiveness to CYC therapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT00004563. Copyright © 2011 by the American College of Rheumatology.
This article was published in Arthritis Rheum and referenced in Rheumatology: Current Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords